60 Degrees Pharma Prices $1M Private Placement Above Market, Adding Warrants and Potential Dilution
SXTP sits 17% above its 52-week low of $1.05.
Summary
60 Degrees Pharmaceuticals raised $1.0 million in a private placement priced at $1.74 per share, a premium to the current $1.23 price, with warrants that could add over 1.1 million shares. The cash extends a tight runway but brings dilution risk.
Key Events · Financing and Capital Events · SXTP
-
Private Placement Priced at Premium
The company sold 191,571 shares at $1.74 and pre-funded warrants for 383,142 shares at $1.739, raising ~$1.0M gross. That share price represents a premium to the current $1.23 market price, signaling institutional demand despite the company's distressed state.
-
Warrant Overhang Adds Dilution Risk
Series A and B warrants were issued to purchase 1,148,826 shares at $1.49, exercisable immediately. If fully exercised, total potential shares from this deal exceed 1.7 million, more than doubling the current outstanding share count.
-
Cash Runway Extension
Proceeds will be used for working capital and R&D. As of May 2026, the company had only a 4-month cash runway; this $1M infusion likely extends operations by a few months but does not resolve the going-concern risk.
-
Registration Rights Add Selling Pressure
A resale registration statement must be filed within 45 days. Once effective, the shares and warrant shares can be sold, potentially weighing on the stock.
Analysis · SXTP · Life Sciences
On July 31, 2026, 60 Degrees Pharmaceuticals closed a $1.0 million private placement, selling shares at $1.74 — a premium to the current $1.23 stock price — alongside pre-funded and common warrants. The deal provides critical working capital for a company with a going-concern warning and only a few months of cash runway, but the warrant coverage (1.15 million shares at $1.49) creates significant potential dilution if exercised. The placement agent also received warrants for 43,103 shares at $2.175. Within 45 days, the company must file a resale registration statement, which could add selling pressure once effective.
At the time of this filing, SXTP was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $1.05 to $8.62. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.